|

Autologous BAFFR-targeting CAR T Cells Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Autologous BAFFR-CAR T Cells, Autologous BAFFR-CAR-expressing T-cells

Pipeline

Phase 1: 1

Top Sponsors

  • Mayo Clinic1

Indications

  • Refractory Marginal Zone Lymphoma1
  • Recurrent Marginal Zone Lymphoma1
  • Refractory Small Lymphocytic Lymphoma1
  • Refractory Chronic Lymphocytic Leukemia1
  • Recurrent Small Lymphocytic Lymphoma1

Jacksonville, Florida1 trial

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Mayo Clinic in Florida

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.